One-Year Outcomes Data from the OptiMesh SCOUT Published

One-Year outcomes data from the OptiMesh SCOUT Spineology® Clinical Outcomes Trial has been published online in SPINE, the journal of the North American Spine Society.

The article, “One Year Outcomes from a Prospective Multicenter Investigation Device Trial of a Novel Conformal Mesh Interbody Fusion Device,” focuses on trial outcomes of patients treated with the OptiMesh Expandable Interbody Fusion System.

The unique OptiMesh device expands in three dimensions, enabling surgeons to perform interbody fusion procedures through an access smaller than any other fusion procedure. Print publication is anticipated before the end of 2020.

SCOUT was a prospective, multicenter investigational device clinical trial. It demonstrated strong outcomes for the OptiMesh implant at one year, including:

  • Significant reduction in back and leg pain1
  • Substantial improvement in functional status that occurred early and was sustained through 12 months1
  • 90 percent “excellent” or “good” patient satisfaction scores1
  • A 98 percent fusion rate1
  • An excellent safety record with no serious, device-related, adverse events1

“We have found this innovative, minimally invasive device to be a safe and effective option for lumbar interbody fusion procedures,” said SCOUT lead investigator John Chi, M.D., M.P.H. Dr. Chi is the Director of Neurosurgical Oncology at Brigham and Women’s Hospital in Boston, Massachusetts, and Associate Professor of Neurosurgery at Harvard Medical School, and the author of the SPINE article. “The outcomes, including high fusion rates, improved function, reduced pain and high satisfaction rates, are very favorable. Additionally, the minimal exposure requirements yielded an exceptional safety profile.”

“Spineology recently received an FDA De Novo Grant for the interbody placement of OptiMesh and is preparing for a Q1 2021 launch,” said John Booth, Spineology’s CEO. “Publication of the SCOUT data is further testimony to the strength of the study. The results demonstrated by OptiMesh along with the experiences of our investigators will help take surgery for low back and leg pain to the next level by providing excellent patient outcomes, enhanced recovery and exceptional efficiency.”

In addition to the SPINE publication, the International Journal of Spine Surgery (IJSS) accepted three manuscripts discussing Spineology’s proprietary mesh technology:


1 Lu Y, Huang K, Lavoie S, Krag M, Nunley P, Bydon M. Preliminary 24-month Outcomes of a Prospective Investigation of a Novel Mesh Interbody Spacer in Single-Level Fusions. Society for Minimally Invasive Spine Surgery (SMISS) Annual Forum 2019. Las Vegas, NV. 2019 Oct 31 – Nov 2.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”